Research press release


Nature Medicine

A drug against blood cancer may also fight lupus


重症筋無力症や全身性エリテマトーデスのような病気は自己抗体が原因で起こるが、これを作るのは寿命の長い免疫細胞で、タンパク質生産を非常に盛んに行っている。骨髄細胞はプロテアソーム阻害剤による治療に反応し、その感受性はタンパク質合成の速度と相関していることから、R Vollたちは、エリテマトーデスに似た病気のマウスでも、これらの阻害剤が自己抗体産生細胞に対して同様な作用を示すだろうと考えた。


A drug used to treat multiple myeloma, a cancer of the white blood cells, could also be useful for the treatment of the chronic autoimmune disease lupus erythematosus. A study published this online week in Nature Medicine suggests that this may lead to new treatment strategies for other antibody-mediated diseases.

Diseases like myasthenia gravis and systemic lupus are caused by autoantibodies produced by long-lived immune cells that show very high rates of protein generation. As myeloma cells respond to treatment with proteasome inhibitors, and their sensitivity correlates with their rates of protein synthesis, Reinhard Voll and his colleagues suggest that, in mice with lupus-like disease, those inhibitors would have a similar effect on the autoantibody-producing cells.

Using two mouse strains with ‘lupus’ they show that the proteasome inhibitor bortezomib ? a drug approved for the treatment of multiple myeloma ? blocks autoantibody production and prolongs survival of the mice. So, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-associated diseases.

doi: 10.1038/nm1763


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。